Regeneron Pharmaceuticals, Inc.

Informe acción NasdaqGS:REGN

Capitalización de mercado: US$80.0b

Salud financiera de hoja de balance de Regeneron Pharmaceuticals

Salud financiera controles de criterios 5/6

Regeneron Pharmaceuticals tiene un patrimonio de accionistas total de $29.3B y una deuda total de $2.0B, lo que sitúa su ratio deuda-patrimonio en 6.8%. Sus activos y pasivos totales son $37.4B y $8.1B respectivamente. El BAIT de Regeneron Pharmaceuticals es de $4.1B, por lo que su ratio de cobertura de intereses es de -6.7. Tiene efectivo e inversiones a corto plazo que ascienden a $9.8B.

Información clave

6.8%

Ratio deuda-patrimonio

US$1.98b

Deuda

Ratio de cobertura de intereses-6.7x
EfectivoUS$9.80b
PatrimonioUS$29.33b
Total pasivoUS$8.12b
Activos totalesUS$37.44b

Actualizaciones recientes sobre salud financiera

Recent updates

Regeneron: The Biotech Stock To Buy Now

Nov 19

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($19.3B) de REGN superan a sus pasivos a corto plazo ($3.7B).

Pasivo a largo plazo: Los activos a corto plazo de REGN ($19.3B) superan a sus pasivos a largo plazo ($4.5B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: REGN tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de REGN ha crecido de 0% a 6.8% en los últimos 5 años.

Cobertura de la deuda: La deuda de REGN está bien cubierta por el flujo de caja operativo (214.1%).

Cobertura de intereses: REGN gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.


Hoja de balance


Descubre empresas con salud financiera